Table 3: Relation between genetic variables and clinical response to methotrexate.

Response ( )Nonresponse ( ) valueOR (95% CI)

MTHFR C677T, rs1801133
 CC 52 (49.5)53 (50.5)Reference
 CT46 (46.5)53 (53.5)0.6621.13 (0.65–1.96)
 TT7 (24.1)22 (75.9)0.0153.08 (1.21–7.84)
 CC 52 (49.5)53 (50.5)Reference
 T carrier53 (41.4)75 (58.6)0.2151.39 (0.83–2.33)
 C carrier98 (48.0)106 (52.0)Reference
 TT7 (24.1)22 (75.9)0.0152.91 (1.19–7.10)

ATIC T675C, rs4673993
 TT48 (43.6)62 (56.4)Reference
 TC40 (40.4)59 (59.6)0.6371.14 (0.66–1.98)
 CC17 (70.8)7 (29.2)0.0160.32 (0.12–0.83)
 TT48 (43.6)62 (56.4)Reference
 C carrier57 (46.3)66 (53.7)0.6790.90 (0.53–1.50)
 T carrier 88 (42.1)121 (57.9)Reference
 CC17 (70.8)7 (29.2)0.0070.30 (0.12–0.75)

Results are expressed in (%).
value < 0.05 is considered to be of statistical significance (highlighted in bold).
ATIC: 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase; C: cytosine; CI: confidence interval; MTHFR: methylenetetrahydrofolate reductase; OR: odds ratio; T: thymine.